Mycobacterium tuberculosis is an important global pathogen for which new drugs are
urgently required. The ability of the organism to survive and multiply within macrophages …

One of the significant challenges to treat tuberculosis is the phenotypic resistance adapted
by the latent or dormant Mycobacterium tuberculosis (M. tuberculosis) cells against most of …

A cellular activity-based screen on Mycobacterium tuberculosis (Mtb) H37Rv using a
focused library from the AstraZeneca corporate collection led to the identification of 2 …

Tuberculosis is a disease of global importance for which novel drugs are urgently required.
We developed a whole-cell phenotypic screen which can be used to identify inhibitors of …

The rise of drug‐resistant Mycobacterium tuberculosis (Mtb) has extended the duration of
tuberculosis (TB) treatment and reduced the likelihood of cure. One strategy to combat this …

Here we describe the development and validation of an intracellular high-throughput
screening assay for finding new antituberculosis compounds active in human macrophages …

Drug resistance in Mycobacterium tuberculosis is an emerging threat that makes the
discovery of new candidate drugs a priority. In particular, drugs with high sterilizing activity …

Drug resistance in Mycobacterium tuberculosis is relentlessly progressing while only a
handful of novel drug candidates are developed. Here we describe a GFP-based high …

Identification of compounds that target metabolically diverse subpopulations of
Mycobacterium tuberculosis (Mtb) may contribute to shortening the course of treatment for …

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a leading cause of
morbidity and mortality worldwide. With the increased spread of multi drug-resistant TB …